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1. INTRODUCTION
1.1. ORAL DRUG DELIVERY
Oral drug delivery is the most widely utilized route of administration among all
the routes of administration that has been explored for the systematic delivery of drug
through different pharmaceutical dosage forms. The popularity, of oral drug delivery
may be in partly attributed to its ease of administration as well as the traditional belief
that by oral administration, the drug is well absorbed because of the food stuff that are
ingested daily. In fact, the development of a pharmaceutical product for oral delivery,
irrespective of its physical form(solid, semisolid or liquid dosage forms), involves
various extent of optimization of dosage form characteristics within the inherent
consistent of gastro intestinal physiology.1
The oral route of drug administration is the most important method of drugs for
systematic affects. It can be said that at least 90% of all drugs used to produce
systemic effect by oral route of drugs that are administered orally, solid oral dosage
forms represents the preferred loss of product because in this form one usual dose of
the drug has been accurately placed.2
1.2. ORAL CONTROLLED RELEASE DOSAGE FORMS
Oral drug delivery system is the most popular route, which is due in part to the
ease of administration and to the fact that gastrointestinal physiology offers more
flexibility in dosage form design than most other routes. There is a plethora of oral
controlled release products in the market place. Over the past decades the treatment of
illness has been accomplished by administering dosage forms, like tablets, capsules,
pills, creams, ointments, liquid, aerosols, injectables and suppositories.
These conventional drug delivery systems are still the primary pharmaceutical
products commonly seen today in the prescription and OTC drug market place. To
achieve and maintain the drug concentration in the body with in the therapeutic range
required for a medication, it is often necessary to take this type of drug-delivery
system several times a day. This results in a see saw pattern drug level. 3
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Figure 1: Fluctuating drug levels and frequent dosing in case of IR products
Figure 2: Drug blood level time curve for a controlled release product
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A number of technical advancements have been recently made in developing
new technologies for the rate of drug ,delivery sustaining the duration of the
therapeutic action and /or targeting the delivery of drug to a tissue.  These
advancements have already led to the development of several novel drug drug
delivery systems that could provide one/more of the following.4
1) Controlled administration of a therapeutic dose at a desirable delivery state.
2) Maintenance of drug concentration within an optimal therapeutic range for
prolonged duration of treatment.
3) Maximization of efficacy-dose relationship.
4) Reduction of side effects.
5) Maximization of the needs for fragments dose intake and patient compliance.
1.3. ADVANTAGES AND DISVANTAGES OF ORAL
CONTROLLED  RELEASE  DELIVERY SYSTEM
Development of oral controlled release dosage forms of a given drug involves
optimization of the dosage form characteristics within the inherited constrains of the
gastrointestinal physiology. Controlled release delivery systems have added
advantages over immediate release dosage form.
Advantages:
 Maintenance of plasma drug concentration within an optimal therapeutic range
for prolonged duration of treatment.
 Reduction of dosing frequency by administering the drug once or twice a day.
 Drug administration can be more convenient due to  reduction of
gastrointestinal side effects.
 Less fluctuation of plasma drug level and leads to more uniform drug effect
and lesser total dose.
 Maximization of efficiency-dose relationship.
 Improved patient compliance.
 Minimize or eliminate local side effects.
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 Employ less total drug than that in combined conventional dosage forms.
 Minimize drug accumulation with chronic dosing.
 Reduction in health care costs.i.e, the average cost of treatment over an
extended time period may be less with lesser frequency of dosing.
Disadvantages:
One the other hand, controlled release dosage forms have some disadvantages
which include,
 Relatively poor in-vitro/in-vivo correlation.
 Increased variability among dosage units.
 Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity
reaction.
 Need for additional counseling of patients.
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1.4 .CONTROLLED RELEASE FORMULATIONS
Table no.1: Type of controlled release system
I.TYPES OF CONTROLLED RELEASE TABLETS
1. Matrix type tablets
a) Hydrophobic and hydrophilic matrices.
b)   Plastic matrices.
c)   Ion exchanges resins.
d)  Co-precipitates and solid dispersions.
TYPE OF SYSTEM RATE CONTROLLING MECHANISM
Diffusion controlled
 Reservoir system
 Monolithic system
Water permeation controlled
 Osmotic system
 Swelling system
Chemically controlled
 Monolithic system
 Pendent system ion
exchange resins
Regulated systems
 Magnetic, ultrasound
 Chemical
Diffusion through a membrane
Osmotic transport of water through a semi
permeable membrane
Water penetration into a glassy polymer
Either pure polymer erosion (surface
erosion)or a combination of erosion and
diffusion(bulk erosion)
Combination of hydrolysis of the pendent
group and diffusion from the bulk polymer
Exchange of acidic or basic drugs with ions
present
External application of magnetic field or
ultrasound device
Use of competitive desorption or enzyme
substrate reactions. Rate control is built into
the device.
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2. Film-Coated tablets
a) Diffusion-controlled membranes.
b) Osmotic pumps.
c) Enteric coating tablets.
d) Floating tablets.
e) Swellable tablets.
f) Mucoadhesive tablets.
g) Complexation.
h) Cyclodextrins.
i) Pharmaceutical adhesives.
3. Multiple-unit tablets
II. CAPSULES
a)  Hard capsules
b)  Soft elastic capsules
c)   Floating capsules
III. Micro granules/spheroids
IV. Beads
V. Pellets
VI. Emulsions
VII. Suspensions
VIII. Liposome’s
IX. Micro particles
X. Nano particles
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1.5. MATRIX SYSTEMS
Types of oral controlled release tablets
1) Matrix type/matrix systems.
2) Film coating tablets.
3) Multiple unit tablets
1.5.1. Matrix tablets:
These are the simplest and least expensive system for controlled drug delivery.
Their processing is reproducible and is similar to that conventional system. The
polymer or other carrier is homogeneously mixed with drug.
Drug release from the bulk of matrix involves two matrix mechanisms:
1) The erosion rate of the matrix determines the drug release state in matrices
governed by erosion or dissolution
Eq. (1)
Where:
- Drug release rate.
S - Surface area
- Matrix erosion rate
- Drug Concentration gradient
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2)  The diffusion through a barrier membrane describes drug release in insoluble
coating via fick’s second law of diffusion.
Eq. (2)
Where:
D – Diffusion coefficient
S – Exposed surface area
K –Partition coefficient
– Drug concentration gradient
1.5.2. Avantages of matrix system
Unlike reservoir and osmotic systems, products based on matrix design  can be
manufactured using conventional processes and equipment’s. Secondly, development
cost and time associated with the matrix system are viewed as variables, and no
additional capital investment is required. Lastly, a matrix system is capable of
accomodating both low and high drug loading and active ingredients with a wide
range of physical and chemical properties.
1.5.3. Limitation of the matrix systems
As with any technology, matrix systems come with certain limitations. First
matrix systems lack flexibility in adjusting to constantly changing dosage levels as
required by clinical study outcome. When new dosage strength is deemed necessary,
more often than not a new formulation and thus additional resources are expected.
Furthermore, for some products that require unique release profiles (dual release or
delayed plus extended release), more complex matrix-based technologies such as
layered tablets are required.
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1.5.4. Types of matrix  systems
The matrix system can be divided into two categories depending on the types of
retarding agent or polymeric materials.
1.5.4 (a) Hydrophobic matrix system
This is the only system where the use of polymer is not essential to provide
controlled drug release, although insoluble polymers have been used. As the term
suggests, the primary rate-controlling components of hydrophobic matrix are water
insoluble in nature. These ingredients include waxes, glycerides, fatty acids, and
polymeric materials such as ethyl cellulose, methyl cellulose and acrylate copolymer.
To modulate drug release, it may be necessary to incorporate soluble ingredients such
as lactose into formulation. The presence of insoluble ingredient in the formulations
helps to maintain the physical dimension of hydrophobic matrix during drug release.
As such, diffusion of active ingredient from the system is the release mechanism, and
the corresponding release characteristic can be described by Higuchi equation known
as square root of time release kinetic. The square root of time release profile is
expected with a porous monolith, where the release from such system is proportional
to the drug loading. In addition, hydrophobic matrix systems generally are not suitable
for insoluble drug because the concentration gradient is too low to render adequate
drug release. As such, depending on actual ingredient properties or formulation
design, incomplete drug release within the gastrointestinal transit time is a potential
risk and need to be delineated during the development. With the growing needs for
optimization of therapy, matrix systems providing programmable rates of delivery
become more important. Constant rate delivery always has been one of the primary
targets of controlled release system especially for drug with narrow therapeutic index.
.1.5.4 (b) Hydrophilic matrix system
The primary rate limiting ingredients of hydrophilic matrix are polymers that
would      swell on contact with aqueous solution and form a gel layer on the surface
of the system. When the release medium (i.e. water) is thermodynamically compatible
with a polymer, the solvent penetrates into the free spaces between macromolecular
chains. The polymer may undergo a relaxation process, due to the stress of the
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penetrated solvent, so that the polymer chains become more flexible and the matrix
swells. This allows the encapsulated drug to diffuse more rapidly out of the matrix.
On the other hand, it would take more time for drug to diffuse out of the matrix since
the diffusion path is lengthened by matrix swelling. Moreover, it has been widely
known that swelling and diffusion are not the only factors that determine the rate of
drug release. For dissolvable polymer matrix, polymer dissolution is another
important mechanism that can modulate the drug delivery rate. While either swelling
or dissolution can be the predominant factor for a specific type of polymers, in most
cases drug release kinetics is a result of a combination of these two mechanisms. The
presence of water decreases the glassy-rubbery temperature (for HPMC from 184°C
to below 37°C), giving rise to transformation of glassy polymer to rubbery phase (gel
layer). The enhanced motility of the polymeric chain favors the transport of dissolved
drug. Polymer relaxation phenomena determine the swelling or volume increase of the
matrix Boniferoni et al. (1995) showed a relationship between rheological behavior of
HPMC gels and their erosion rate, conforming that the polymer-polymer and
polymer-water interaction are responsible for the gel network structure and its
sensitivity to erosion. In turn, they affect drug release rate in the case of poorly
soluble drugs.6
Swelling controlled release systems are based upon these principles. Due to the
viscoelastic properties of the polymer which are enhanced by the presence of cross-
linked network, anomalous penetrant transport can be observed. This behavior is
bound by pure Fickian diffusion and case II transport. Therefore, transport can be
reduced to three driving forces. The penetrant concentration gradient, polymer
concentration gradient and osmotic force behavior are observed as a result of polymer
network. Appropriate polymer can counterbalance normal Fickian diffusion by
hindering the release of embedded drug, leading to an extended period of drug
delivery, and possibly zero-order release.
Drug release from swell able matrix tablets can be affected by glassy-rubbery
transition of polymer (as a result of water penetration into the matrix where
interaction among water, polymer and drug or fillers is considered as the primary
factor for release control) and the various formulation variables, such as polymer
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grade and type, drug to polymer ratios, drug solubility, drug and polymer particle
sizes, compaction pressure and presence of additives or excipients in the final
formulation.
1.6. DRUG RELEASE FROM MATRIX SYSTEMS
1.6.1. Mechanism of drug release from swelling controlled release systems
1.6.1 (a) Polymer swelling and drug release
The overall drug release mechamism from swelling controlled release systems
based pharmaceutical devices strongly depends on the design (composition and
geometry) of the particular delivery system. When a matrix comes in contact with an
aqueous solution, wetting occurs first at the surface and then progresses by way of
microscopic pore spaces into the matrix. The excipient in the matrix also absorb
water, hydrates and swell to block up the existing pores, dissolves the content to
create  a more porous structure, gels to form a more viscous solution giving rise to
positive pressure opposing liquid entry or causes disintegration of the matrix. Before a
liquid can enter a matrix, there must be a driving force, which is derived from the
pressure difference. The rate of liquid penetration into the matrix is determined by
balance of this force promoting fluid entry towards the interior and the viscous force
opposing it, which soon develops as soluble excipients in matrix dissolve or swell.
The swelling of the matrix and consequent drug release by diffusion from the matrix
and erosion of the matrix is shown in Figure 3a and 3b.
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Figure 3(a) Drug release controlled by polymer erosion;
3(b) Drug release controlled by swelling and erosion.
A hydrophilic matrix, controlled-release system is a dynamic one involving
polymer wetting, polymer hydration, gel formation, swelling, and polymer
dissolution. At the same time, other soluble excipients or drugs will also wet,
dissolve, and diffuse out of the matrix while insoluble materials will be held in place
until the surrounding polymer/excipient/drug complex erodes or dissolves away. The
mechanisms by which drug release is controlled in matrix tablets are dependent on
many variables. The main principle is that the water-soluble polymer, present
throughout the tablet, hydrates on the outer tablet surface to form a gel layer.
Throughout the life of the ingested tablet, the rate of drug release is determined by
diffusion (if soluble) through the gel and by the rate of tablet erosion.8
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A detailed description of the swelling, erosion and drug release process can be
described as follows.
i). At the beginning of the process, steep water concentration gradients are formed at
the polymer water interface resulting in water imbibitions into the matrix. In dry
systems the diffusion coefficient is very low, whereas in highly swollen gels it is of
the same order of magnitude as pure water. Water acts as a plasticizer and reduces the
glass transition temperature (Tg) of the system. Once the Tg equals the temperature of
the system, polymer chains undergo the transition from the glassy to the rubbery
states shown in Figure 4. The glass transition temperature Tg, of a polymer is an
important characteristic constant, in particular with respect to applications in the field
of controlled drug delivery. Below the Tg the mobility of the macromolecules is very
low9. The material is in its glassy state resulting in extremely small diffusion. In
contrast, above the glass transition temperature the mobility of the polymer chains is
markedly increased (rubbery state), leading to much higher mass transfer rates of
water and drug. For instance Tg for HPMC is reported to be 154 to 184oC.10
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Figure 4: Drug concentration profile as a function of glass and rubbery regions9.
ii). The imbibitions of water and formation of rubbery region; which externally
appears as polymer swelling results in dramatic changes of polymer and drug
concentrations, and increasing dimensions of the system. The polymer chains unfold,
and gradually become solvated, voids created as the polymer unfolds is occupied by
water molecules. The apparent volume occupied by these expanded coils is referred to
as the hydrodynamic volume.
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Figure 5: Different front position observed during matrix swelling and erosion.
iii). Upon contact with water the drug dissolves and (due to concentration gradient)
diffuses out of the device. Three fronts are observed as shown in Figure 5.11 The
Swelling front, identifying the boundary between the still glassy polymer and its
rubbery gel state. The boundary between the still undissolved (solid) drug and the
dissolved drug in the gel layer is indicated by diffusion front and erosion front
identifies the boundary between matrix and dissolution medium. Gao et al. (1996)
studied the swelling behavior of HPMC matrices using Adinazolam mesylate as the
model drug, and concluded that swelling is anisotropic with preferential expansion in
the axial direction; swelling is isotropic with respect to the gel layer thickness and
composition in both axial and radial directions.
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Figure 6: Gel layer thickness as a function of time.
iv). With increasing water content the diffusion coefficient of the drug increases
substantially. It is to be noted that during drug delivery, as swelling and dissolution of
the polymer compete, the gel layer thickness first increases due to swelling (Region a
in Figure 6), then remains constant due to synchronization of swelling, drug diffusion,
and dissolution (Region b) and finally decreases (Region c) as dissolution takes over.
Thus finally the release of drug is complete as the matrix erodes. The drug
release from a swelling matrix system thus can be summed up to be governed by
drug diffusion through the matrix and polymer erosion. It is to be noted that in the
case of poor water-solubility, dissolved and undissolved drug coexist within the
polymer matrix. Undissolved drug is not available for diffusion. In the case of high
initial drug loadings, the inner structure of the matrix changes significantly during
drug release, becoming more porous and less restrictive for diffusion upon drug
depletion. Depending on the chain length and degree of substitution of the HPMC
type used, the polymer itself dissolves more or less rapidly (erosion of the polymer).
In certain cases this phenomenon is negligible, for example if all the drug has already
been released before polymer dissolution becomes important.
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1.6.1. (b) Polymer erosion
Polymer chain dissolution from the matrix involves two distinguishable processes as
depicted in Figure 8.
 The first step involves disentanglement of the individual molecules at matrix
surface, which depend on rate of hydration. This occurs at a critical polymer
concentration, defined as ‘polymer disentanglement concentration. This polymer
concentration depends on properties of the polymer and solvent.
 The second step involves the transport of these molecules from the surface across
an aqueous diffusion layer, adjacent to the matrix, to the bulk solution12
Figure 7: A system showing polymer erosion, (a) initial polymer entanglement in
the matrix, (b) reptating chain disentangling from the system and (c) finally
disentangling from the system.
Here the disentanglement of the “bold” chain is considered. A test chain in an
entangled system of chains is shown in (Figure 7a). When solvent penetrates into this
system, the mobility of the test chain increases, and the chain begins to exhibit
“reptation”. Reptation causes the test chain to disentangle from the system (Figure
7b). The test chain completely disentangled from the original system is shown in
(Figure 7c).
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1.6.2. POLYMERS USED IN MATRIX SYSTEMS 13
Tablet formation is one way of designing a controlled release form. Depending
on the type of formulation or processing technique a number of parameters need to be
controlled in matrix systems. Some examples illustrate such parameters used in
polymer resin, plastic or wax based matrices. The chemical and physical effects of
polymers on matrix have been reported. Chemical effects include water vs. solvent
solubility, hydration gel formation and physical wettability, porosity, viscosity,
cohesiveness, permeation and so on. Some examples follow:
Types of polymers used in matrix systems
1) Insoluble, inert
a) Poly ethylene
b) Poly vinyl chloride
c) Methyl acryl ate – methacrylate copolymers
d) Ethyl cellulose
2) Insoluble, erodible ( Fatty compounds )
a) Carnauba wax
b) Stearyl alcohol
c) Stearic acid
d) Poly ethylene glycol
e) Castor wax
f) Poly ethylene glycol mono stearate
g) Tri glycerides
3) Hydrophilic polymers
a) Methyl cellulose
b) Hydroxy ethyl cellulose
c) Hydroxy propyl methyl cellulose
d) Sodium carboxy methyl cellulose
e) Sodium alginate
f) Poly ethylene oxide
g) Poly vinyl alcohol
h) Galacto mannose
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i) Carbopol
j) Hydroxy propyl cellulose
k) Guar gum
l) Alginic acid
m) Chitosan
n) Pectin
ETHYL CELLULOSE (EC):
 It is an insoluble, inert (plastic materials) type of polymer.
 Increasing the amount of EC resulted in decreased release rate.
HYDROXY PROPYL CELLULOSE (HPC):
 It is hydrophilic polymer. Mechanistic studies of HPC have shown gel
formation, dissolution and diffusion to be important in controlling release.
 HPC > EC aqueous solutions 0.5% concentration have decreased viscosities in
the order shown.
 Increasing the HPC concentration and viscosity decreases release rate of drugs.
Possibly to both decreased porosity and cohesiveness of the matrix.
HYDROXY PROPYL METHYL CELLULOSE (HPMC):
 It is hydrophilic polymer. As amount of HPMC in the mixtures was increased
dissolution of gel layer took place in addition to diffusion.
 Additives can be used to modify wettability of the pores and thus further
increased and decreased the porosity14.
 Release occurs initially from the surface particles via dissolution followed by
pore formation in the area of the displaced surface drug particles with further
solute diffusion.
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HYDROXY ETHYL CELLULOSE
 Hydroxy ethyl cellulose is a non ionic, water-soluble polymer it in
combination with Hydroxy propyl cellulose forms a good matrix system.
1.7. NEED FOR INVESTIGATION OF DRUG
Drug is a highly lipid soluble BCS class II drug used as an antihypertensive for
the treatment of hypertension, angina pectoris. It is a yellow crystalline solid,
insoluble in water (˂10mg/L). The dose of the drug ranges from 10mg per day and  its
steady state half life is relatively short(11/2-2hr).The bioavailability is very limited
(15-24%) due to the hepatic first pass effect. While extended release of drug were
originally developed to reduce or eliminate unwanted effects such as gastrointestinal
disturbances, nausea, and vomiting; the short half life of the drug also indicates the
need for modified release dosage form. Modified release solid oral dosage forms offer
the advantages of improved patient compliance and decreased side effects. Majority
of oral sustained and controlled release drug delivery systems are based on either gel
forming matrix or coated formulations, or the combination thereof. Matrix tablet
systems are most popular due to ease in scale-up.  The drug is currently available in
market as immediate release tablet and as an extended release capsule. At present the
extended release tablets available in the market uses osmotic pressure to deliver the
drug at a controlled rate over approximately 24 hours. The present research endeavor
was directed towards the development of matrix tablets to be taken once daily
reducing the price of drug and make the drug more affordable to the patients.
The value of hydrophilic, polymer based matrix system as carriers for controlled drug
delivery is well recognized and increasingly demonstrated by the numerous patents,
research papers, and U.S.FDA approved matrix based products. In particular, water
soluble cellulose ethers (e.g., HPMC, HPC, HEC, EC), PEO, polyvinyl alcohols,
carbopol, and polysaccharides such as xanthan gum; chitosan, alginic acid, pectin, and
guar gum have been extensively used.
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1.8. HYPERTENSION
Hypertension is a chronicmedicalcondition in which the blood pressure is
elevated. It is also referred to as high blood pressure or shortened to HT, HTN or
HPN. The word "hypertension", by itself, normally refers to systemic, arterial
hypertension.
Hypertension can be classified as either essential (primary) or secondary.
Essential or primary hypertension means that no medical cause can be found to
explain the raised blood pressure and represents about 90-95% of hypertension cases.
Secondary hypertension indicates that the high blood pressure is a result of (i.e.,
secondary to) another condition, such as kidney disease or tumours (adrenal adenoma
or pheochromocytoma)
Causes of Hypertension
1.8.1. Essential hypertension15:
Essential hypertension is the most prevalent hypertension type, affecting 90-
95% of hypertensive patients Although no direct cause has identified itself, there are
many factors such as sedentary lifestyle, stress, visceral obesity, potassium deficiency
(hypokalemia) obesity (more than 85% of cases occur in those with a body mass
index greater than 25), salt (sodium) sensitivity, alcohol intake, and vitamin D
deficiency. Risk also increases with aging, some inherited genetic mutations and
family history. An elevation of renin, an enzyme secreted by the kidney, is another
risk factor, as is sympathetic nervous system over activity. Insulin resistance which is
a component of syndrome X, or the metabolic syndrome is also thought to contribute
to
hypertension. Recent studies have implicated low birth weight as a risk factor for
adult essential hypertension.
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1.8.2. Secondary hypertension:
Secondary hypertension by definition results from an identifiable cause. This
type is important to recognize since it's treated differently than essential type by
treating the underlying cause. Many secondary causes can cause hypertension; some
are common and well recognized secondary causes such as Cushing's syndrome,
which is a condition where both adrenal glands can overproduce the hormone cortisol.
Hypertension results from the interplay of several pathophysiological mechanisms
regulating plasma volume, peripheral vascular resistance and cardiac output, all of
which may be increased. More than 80% of patients with Cushing's syndrome have
hypertension.] Another important cause is the congenital abnormality coarctation of
the aorta
1.8.3. Mechanism of hypertension:
Most of the mechanisms associated with secondary hypertension are generally fully
understood. However, those associated with essential (primary) hypertension are far
less understood. What is known is that cardiac output is raised early in the disease
course, with total peripheral resistance (TPR) normal; over time cardiac output drops
to normal levels but TPR is increased.
Three theoeies have been proposed to explain this:
 Inability of the kidneys to excrete sodium, resulting in natriuretic factors such
as is Atrial Natriuretic Factor being secreted to promote salt excretion with the
side effect of raising total peripheral resistance.
 An overactive Renin-angiotensin system leads to vasoconstriction and
retention and symptoms are especially important of sodium and water. The
increase in blood volume leads to hypertension.
 An overactive sympathetic nervous system, leading to increased stress
responses.
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It is also known that hypertension is highly heritable and polygenic (caused by
more than one gene) and a few candidate genes have been postulated in the etiology
of this condition.
Recently, work related to the association between essential hypertension and
sustained endothelial damage has gained popularity among hypertension scientists. It
remains unclear however whether endothelial changes precede the development of
hypertension or whether such changes are mainly due to long standing elevated Blood
Pressure.
1.8.4 Symptoms of hypertension:
Mild to moderate essential hypertension is usually asymptomatic. Accelerated
hypertension is associated with headache, somnolence, confusion, visual disturbances,
and nausea and vomiting (hypertensive encephalopathy). Some signs and symptoms
are especially important in infants and neonates such as failure to thrive, seizure,
irritability or lethargy, and respiratory distress In children, hypertension may cause
headache, fatigue, blurred vision, epistaxis, and bell palsy.
Some signs and symptoms are especially important in suggesting a secondary
medical cause of chronic hypertension, such as centripetal obesity, "buffalo hump,"
and/or wide purple abdominal striae and maybe a recent onset of diabetes suggest
glucocorticoid excess either due to Cushing's syndrome or other causes..
Treatment of hypertension:
There are several types of antihypertensive agent;s
1. Adreno receptor blocking agents.
2. Diuretics.
3. Vasodilators.
A) Calcium Channel Blockers,
B) Directly Acting Vasodilators.
4. ACE inhibitors.
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5. 5-HT antagonist.
1.8.5 Mechanism of action Calcium channel blockers: 16
Calcium channel blockers work by blocking voltage-gated calcium channels
(VGCCs) in cardiac muscle and blood vessels. This decreases intracellular calcium
leading to a reduction in muscle contraction. In the heart, a decrease in calcium
available for each beat results in a decrease in cardiac contractility. In blood vessels, a
decrease in calcium results in less contraction of the vascular smooth muscle and
therefore an increase in arterial diameter (CCB's do not work on venous smooth
muscle), a phenomenon called vasodilation. Vasodilation decreases total peripheral
resistance, while a decrease in cardiac contractility decreases cardiac output. Since
blood pressure is determined by cardiac output and peripheral resistance, blood
pressure drops.
With a relatively low blood pressure, the after load on the heart decreases; this
decreases the amount of oxygen required by the heart. This can help ameliorate
symptoms of ischemic heart disease such as angina pectoris.
Unlike β-blockers, calcium channel blockers do not decrease the responsiveness
of the heart to input from the sympathetic nervous system. Since moment-to-moment
blood pressure regulation is carried out by the sympathetic nervous system (via the
baroreceptor reflex), calcium channel blockers allow blood pressure to be maintained
more effectively than do β-blockers.
However, because calcium channel blockers result in a decrease in blood
pressure, the baroreceptor reflex often initiates a reflexive increase in sympathetic
activity leading to increased heart rate and contractility. A β-blocker may be
combined with a dihydropyridine calcium channel blocker to minimize these effects.
Ionic calcium is antagonized by magnesium ions in the nervous system.
Because of this, dietary supplements of magnesium oxide and other magnesium
preparations may increase or enhance the effects of calcium channel blockade.
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LITERATURE REVIEW
1. Harekrishna Roy., (2010) et.al .44 studied the design and in vitro evaluation of
sustained release matrix tablets of complexed nicardipine hydrochloride by employing
hydrophilic and hydrophilic polymers. Due to poor water solubility of the drug its
bioavailability is dissolution rate limited. The purpose of the study was to increase the
solubility of Nicardipine by cyclodextrin inclusion complex technique. Kneading
method was employed for preparation of inclusion complexes. Among different
complexes, a complex with 1:1 molar ratio of drug and β‐CD showed the highest
dissolution rate. Matrix tablets were prepared by direct compression technique using
different concentration of polymers and selected complex. The study has
demonstrated that combination of hydrophobic and hydrophilic polymers effectively
sustained the drug release for prolonged period of time and a minimum of 28 %
sodium alginate is required to retard the release of nicardipine from matrix tablet for
the period of 12 hours.
2. Antesh K Jha., (2009) et.al 45 formulated and evaluated sustained release matrix
tablets of Metoprolol succinate using hydrophilic polymers. The drug belongs to the
category of β1-selective adrenergic receptor blocking agent. The tablets were prepared
by wet granulation method. Ethanolic solutions of ethylcellulose (EC) and
polyvinylpyrrolidone were used as granulating agents along with hydrophilic matrix
materials like hydroxypropyl methylcellulose (HPMC) and guar gum. The results of
dissolution studies indicated that formulation F1 (drug-to-HPMC, 1:4; ethanol as
granulating agent) could extend the drug release up to 12 hours. In the further
formulation development process, F5 (drug-to-HPMC, 1:4; EC 4% w/v as granulating
agent), which is the most successful formulation of the study, exhibited satisfactory
drug release. All the formulations exhibited diffusion- dominated drug release.
3. Dr.Ritesh Patel., (2009) et.al 46 studied the optimization of propranolol
hydrochloride controlled release matrix tablet using factorial design. Direct
compression technique was involved. HPMC K15M and Carbopol 934P were used in
formulating the matrix tablets. A 32 full factorial design were applied for systemic
studies. The blending ratio of HPMC K15M and Carbopol 934P (X1) and polymer
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concentrations (X2) were the independent variables. The times required for 50% (t50)
and 80% (t80) drug release were selected as dependent variables. The results
indicated that the values of t50, t80, f2 and MDT are strongly dependent on the
independent variables. in vitro drug release profile of all batches of factorial design
was compared with theoretical drug release profile. The results indicated that batch F7
showed the highest value among all the batches, and it also shows similarity in t50
and t80 values. The f2 value (74) of batch F7 indicates less than 5% difference in in
vitro drug release profile with theoretical release profile.
4. SH Lakade., (2008) et.al 47 formulated and evaluated sustained release matrix
tablet of anti-anginal drug, and studied the influence of combination of hydrophobic
and hydrophilic matrix former. A hydrophobic polymer (HPMC) and hydrophobic
polymer (Ethyl cellulose) based Nicorandil matrix sustained release tablet which can
release the drug up to a period of 24 hours in predetermined rate was developed. The
formulation of Nicorandil matrix tablet was prepared by the polymer combination in
order to get required theoretical release profile. The influence of hydrophilic and
hydrophobic polymer and granulation technique on Nicorandil was studied. The
formulated tablets were also characterized by physical and chemical parameters. The
in vitro release rate profile should be higher concentration in case of F2. The
combination of hydrophilic and hydrophobic combination showed less result than use
of alone. The in vitro release data was well fit to Peppas and Hixon crowel release
kinetics.
5. Rupali Kale., (2010) et.al; 48 developed matrix diffusion controlled drug delivery
system of pentoxifylline. HPMC formulations showed very high dissolution rate
releasing 70% of drug within two hours but its combination formulation with Eudragit
showed low dissolution rate of 0.14 hour-1. Sodium alginate used did not show
controlled drug release pattern. Eudragit and Guar gum formulations showed low
dissolution rates indicating controlled release pattern of drug but their combination
formulation showed high dissolution rate of 0.73 hour-1.
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6. Anroop B. Nair., et.al.49 formulated controlled release matrix uncoated tablets of
Enalapril Maleate using HPMC alone. Direct compression techniques was used to
prepare the tablets, and were evaluated for physical properties, drug content, in vitro
release and drug release kinetics as well. All the formulations demonstrated good
physical integrity and the drug content were in the official limits. The formulations
with HPMC K 100 (25mg/tablet) and K4M (15mg/tablet) have been found to release
the required amount of drug (2.97mg/h) throughout the study period (14h). The
calculated regression coefficients showed higher r2 value with Higuchi model and
zero order kinetics. Given the excellent release profile, the study concluded that
HPMC in different grades with low concentration alone can control the enalapril
maleate release over a period of 14hours.
7. Hilde Celis, Jan Staessen, Robert Fagard, Lutgarde Thijis, and Antoon
Amery., et al.50 studied effect of modified release 5 mg once daily isradipine on
twelve patient with essential hypertension in a double blind cross over study to
investigate the blood pressure BP-lowering activity, the results shows isradipine
modified release 5 mg influenced the 24 hr BP profile in a different way when
administered in the morning or in the evening as compared to placebo.
8. Saleh A. Al-Suwayeh., et al.51 studied transdermal delivery of isradipine through
excised rabbit skin for the effect of vehicle and drug concentration, the vehicles
namely PEG, ethanol and isradipine . Highest amount of isradipine over 24 hr period
penetrated was achieved in presence of Ethanol.
9. Madhusmruti Khandai, Santanu Chakraborty, Anuradha Sharma,
Debashisha Panda, Nazia Khanam, Santosh Kumar Panda., et al.52 studied on the
development of Propranolol hydrochloride matrix tablets and Investigation on effects
of combination of hydrophilic and Hydrophobic matrix formers like HPMC and EC
and on its in-vitro release, and observed that 10% of each the polymer in combination
was able to produce desire formulation which release more than 90% drug in 12
hours.
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10. Juan G. Puig: Luis M. Ruilope; Rafael Ortega., et al.53 studied the efficacy of
antihypertensive treatment like benazepril in Type II Diabetes Mellitus to confirm the
diagnosis of hypertension and assess the response to antihypertensive therapy.
Antihypertensive drug efficacy was assessed by casual (trough) and 24-hour
ambulatory blood pressure monitoring. Diabetic patients were classified as no
confirmed hypertensive if the mean 24-hour ambulatory diastolic pressure was below
85 mm Hg. Antihypertensive treatment significantly decreased both systolic and
diastolic pressures when determined by either casual measurement (from a mean of
162.7/98.0 to 153.9/89.2 mm Hg; P<.001) or ambulatory monitoring (from a mean of
143.1/84.4 to 137.0/81.5 mm Hg; P<.05).
11. Vaisse. B., Herpin D, Asmar R, Battistella P, Zannad F, Boutelant S, Lyon A,
Co Denis J. Honore., et al.54 Studies on the evaluation of the antihypertensive effect
of drugs according to the initial ambulatory blood pressure (BP) level. In double-blind
design, either bisoprolol (10 mg q.d.) or lisinopril (20 mg q.d.) for 8 weeks. BP
monitoring showed that the antihypertensive effect depended on the baseline mean
24-h value; -15/-12 mm Hg for bisoprolol and -18/-13 mm Hg for lisinopril in the
High group; -7/-6 mm Hg for bisoprolol and -6/-6 mm Hg for lisinopril in the Low
group. This study shows that the antihypertensive effect depended on initial
ambulatory BP values, with a lower BP decrease in the Low group.
12. Panna Thapa, Manish Ghimire, Alex B. Mullen and Howard N.E Stevens., et
al. 55studied on controlled release drug delivery system to investigate the influence of
different diluents, in the release of poorly water soluble drug ibuprofen. Matrix tablet
prepared by wet granulation method at different polymer concentration using lactose,
DCP, MCC and starch. The integrity of the tablets and drug release were found to be
primarily governed by the properties of diluents at low polymer concentration.
13. Bhanja Satyabrata, Ellaiah P, Mohanty Chandan, K.V.R Murthy ,Panigrahi
Bibhutibhusan, Padhy Sudhir Kumar., et al.56 studied on  mucoadhesive buccal
tablet containing antihypertensive drug i.e. Perindopril to avoid the first pass
metabolism and to improve its bioavailability. The tablets were prepared by Prepared
by Sintering Technique containing polymer Polyethylene oxide and carnauba wax.
Chapter-2 Literature review
Dept of Pharmaceutics 29 J. K. K. Nattraja College of Pharmacy
The sintering times and the sintering temperature markedly affected the drug release
properties of Perindopril buccal tablets; the release rate of Perindopril from buccal
tablets was inversely related to the time of sintering and the sintering temperature.
This is may be due to increase in extent and firmness of sintering which compacts the
mass further, so that the drug release is affected. The best in-vitro drug release profile
was achieved with the formulation F4 A (sintered at 600c for 1.5 hr.) which contain
the drug, polyethylene oxide and carnauba wax in the ratio of 1:15:10.The surface pH,
bioadhesive strength and swelling index of formulation F4 A was found to be 6.27,
34.8 gm and 179.31 (after 12 hr). The tablets (formulation F4 A) containing 4 mg of
Perindopril exhibited 8 hrs sustained drug release (98 %) with desired therapeutic
concentration.
14. Rajesh. N, Siddaramaiah and D.V. Gowda., et al.57 studied on the controlled
release behavior of diltiazem hydrochloride from the Pellets of chitosan and
microcrystalline cellulose to minimize the unwanted toxic effects of Diltiazem
Hydrochloride by kinetic control of drug release. 12 ml of deminerlized water was
used as binding agent volume of binding agent increases, irregularly shaped pellets
were produced. As the volume of the binding agent was less than 12 ml, requires
more pressure for compaction and difficult to separate as an individual pellets. The
percent of wetting solution and volume of binding agent has also an effect on the
sphericity of the pellets, confirmed by SEM photographs. Result showed that lowered
drug release was noticed for the systems containing higher content of MCC. Because
swollen MCC particles retards the penetration of dissolution media into pellets and
thus limiting the release of drug from pellets.
15. S. M. Al-Ghannam A. M. Al-Olyan., et al.58 Studied on spectrophotometric
determination of 1, 4-dihydropyridine compounds, nicardipine and isradipine. The
method is based on the reduction of nicardipine and isradipine with zinc powder and
calcium chloride followed by further reduction with sodium pentacyanoaminoferrate
(II) to give violet and red products having the absorbance maximum at 546 and 539
nm with nicardipine and isradipine, respectively. Beer’s law was obeyed over the
concentration range 8.0–180 μg/ml with the detection limit of 1.67 μg/ml for
nicardipine and 8.0–110 μg/ml with the detection limit of 1.748 μg/ml for isradipine.
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The study shows high sensitivity (detection limit = 1.67 for Nicardipine and 1.74
μg/ml for Isradipine).
16. A Smith, J McPherson, M Taylor, A Mason, S Carney and A Gillies (1997) et
al.59 did a comparative study Atenolol and Isradipine.  A 39%reduction of
hypertension was seen with isradipine while 34% reduction with the other. Pro-
haemorrhagic effects of Isradipine were minor when compared to Atenolol.
17. T Fujiwara, Y Ii, J Hatsuzawa, H Murase, T Watanabe, M Murakami, N
Kimura, J Buch, T Tsuchihashi and T Saruta (2009) et al.60 Worked on two
strengths of Amlodipine, an antihypertensive drug. Phase III double-blind parallel-
group controlled study was conducted  to examine the superiority of Amlodipine
10 mg once daily to Amlodipine 5 mg once daily in 305 Japanese outpatients with
essential hypertension .In conclusion, Amlodipine 10 mg once daily was found to be
superior to Amlodipine 5 mg once daily, safe, well tolerated and useful for the
relevant subjects.
18. Lacourcière Y, Poirier L, Dion D, Provencher P et al.61 The antihypertensive
efficacy of sustained-release Isradipine administered once daily compared to the
immediate-release formulation administered twice daily was assessed by ambulatory
blood pressure (BP) monitoring in a double-blind randomized crossover study in 76
mild-to-moderate hypertensive patients. Data suggest that sustained-release Isradipine
has a sustained antihypertensive effect throughout 24 hours comparable to that of
Isradipine given twice daily and may improve compliance with long-term treatment.
In addition, the results confirm the usefulness of ambulatory BP monitoring in
determining truly hypertensive patients likely to respond to drug administration.
19. Bankole A. Johnson, Martin A. Javor, Yui-Wing Francis Lam, Lynda T.
Wells, et al. 62 The authors sought to determine whether sustained-release (SR)
Isradipine provided comparable systemic availability to that of immediate-release (IR)
Isradipine in non-treatment-seeking, cocaine-dependent individuals .The relative
bioavailability of the SR formulation was 55.5% of that of the IR formulation. The
more favorable cardiovascular profile of SR Isradipine would, however, make it more
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appropriate as an investigational medication for the treatment of stimulant dependence
and related neurovascular disorders.
20. Raslan & Maswadeh (2006) et al.63 have studied the effect of HPMC
(hydrophilic) and glyceryl behenate (hydrophobic) polymers on controlled release of
anhydrous Theophylline matrix tablets and studied in vitro release characteristics and
kinetics of prepared formulations for explaining the release pattern from matrix
tablets.
21. Selim., (2003) et al.64 Have done the comparative evaluation of plastic,
hydrophobic and hydrophilic polymers as matrices for controlled-release drug
delivery. They revealed that the drug release from plastic and hydrophobic matrix was
less than hydrophilic polymer. Again, the release pattern of drug from hydrophilic
matrices was closer to zero-order kinetics than that from other classes of matrices.
22. Nair.,(2007) et al.65 Have made an attempt to formulate a controlled-release
matrix tablet formulation for Alfuzosin hydrochloride by using low viscous hydroxyl
propyl methylcellulose (HPMC K-100 and HPMC 15cps) and its comparison with
marketed product. Drug release from the matrix tablets was carried out for 12 hr and
showed that the release rate was not highly significant with different ratios of HPMC
K-100 and HPMC15cps. They concluded that the use of low viscous hydrophilic
polymer of different grades (HPMC K-100 and HPMC 15cps) can control the
Alfuzosin release for a period of 12 hr and were comparable to the marketed product.
23. Gurvinder Singh Rekhi, Ranjani V. Nellore, Ajaz S. Hussain, Lloyd G.
Tillman, Henry J. Malinowski and Larry L. Augsburg., et al 66 worked on
Identification of critical formulation and processing variables for Metoprolol Tartrate
extended-release (ER) matrix tablets. They studied the influence of critical
formulation and processing variables on scale-up of oral extended-release dosage
forms, using hydrophilic polymer hydroxyl propyl methyl cellulose (Methocel
K100LV). They concluded that change in polymer level was the most significant
factor affecting drug release. Increase in Dicalcium phosphate level and compression
force was found to affect the percent released at the later dissolution time points.
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24. Raghavendra rao G, Gandhi Sagar, Patel Tarun., et al.67 work was to develop
sustained release matrix tablets of water soluble Tramadol hydrochloride using
different polymers viz. hydroxy propyl methyl cellulose (HPMC) and natural gums
like Karaya gum (KG) and Carrageenan (CG). Zero order kinetics via, swelling,
diffusion and erosion and the release profile of test formulation were comparable with
the marketed product.
25. Sevgi Takka, Adel Sakr, Arthur Goldberg., et al.68 study was to develop an in-
vitro–in-vivo correlation (IVIVC) for two Buspirone hydrochloride extended release
formulations and to compare their plasma concentrations over time with the
commercially available immediate release (IR) tablets developed two types of
formulations using methocel high and low viscosity grades and evaluated that these
will control the release.
26. K.Mahalingan, S.Rajarajan, N.Sree Harsha., (2009). et al.69 study to
investigate the formulation development of orally administrable Clarithromycin
delayed release tablet. Clarithromycin tablet was designed for the delaying the
release to prolong the duration of drug action with the help of various polymers like
Microcrystalline Cellulose, HPMC K4M, HPMC K5M, HPMC6CPS, PEG 6000 with
different additives are used for the trial and error method .preliminary results from
this study suggest that tablets prepared from MCC, HPMC 6CPS and PEG 6000 can
be used to incorporate antibiotics like Clarithromycin and may be effective when
administered orally in the stomach against H. pylori.
27. Brijesh S. Dave, Avani F. Amin, and Madhabhai M. Patel.., et al.70 purpose of
this research was to prepare a gastroretentive drug delivery system of Ranitidine
hydrochloride. Guar gum, xanthan gum, and hydroxyl propyl methyl cellulose were
evaluated for gel-forming properties. By selecting a suitable composition of release
rate enhancer (citric acid) and release rate retardant (stearic acid), the desired
dissolution profile can be achieved.
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28. M. Harris shoaib, Jaweria Tazeen, Hamid  Merchant and Rabia Ismail
Yousuf ., et al.71 Develop a once-daily sustained release matrix tablet of ibuprofen
using hydroxyl propyl methyl cellulose (HPMC) as release controlling factor and to
evaluate drug release parameters as per various release kinetic models. In order to
achieve required sustained release profile tablets were directly compressed using
Avicel PH 101 and Magnesium stearate. Ibuprofen sustained release matrix tablet was
prepared successfully using HPMC as polymer to retard release and achieve required
dissolution profile. Drug release kinetics of this formulation correspond best to
Higuchi’s model and drug release mechanism as per n value of Korsmeyer &Peppas
(Power law) cannot be predicted clearly as it appears to be a complex mechanism of
swelling, diffusion and erosion.
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3: AIM AND OBJECTIVE
3.1. AIM:
The aim of the present study is to develop a pharmaceutically stable, cost
effective and quality improved, once in a day formulation of Isradipine controlled
release Matrix tablets by using synthetic polymer HPMC of different grades.
3.2. OBJECTIVE:
The concept of controlled drug delivery has been explored for the delivery of
soluble and insoluble drugs for prolong period of time for the past few years. This
type of drug delivery seems to provide a solution to several problems encountered in
the course of design of the dosage form for such molecules. Utilizing the concept of
incorporating drug in to the polymer matrices and extend the drug release for prolong
period of time an attempt was made to design and evaluate a matrix tablets for a
insoluble drug facilitating drug release by diffusion of the matrix using materials like
polymers, waxes like hydrophilic and hydrophobic polymers to obtain the controlled
release of the drug in vitro.
Isradipine belongs to dihydropyridine derivative, which is used as an anti-
hypertensive agent and also as vasodilator since it is a calcium antagonist compound
(calcium channel blockers). Isradipine is practically insoluble in water and its
dissolution is rate limited by its physiochemical properties. Isradipine has a half life
1.5 to 8 hours and usual oral dosage regimen 2.5 mg to 20 mg. Also it undergoes
extensive first-pass metabolism, resulting in a low bioavailability of 15%-24%. Hence
to reduce the frequency of administration and to improve patient compliance, a once-
daily controlled release formulation of Isradipine is desirable. Hydrophilic polymer
matrix system were widely used in oral controlled drug delivery ,because they make it
easier to achieve a desirable drug-release profile, they are cost effective and have US-
FDA (Food Drug Administration) acceptance.
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To achieve this goal various prototype formulation trials were taken and
evaluated with respect to the various quality control tests such as dissolution, assay.
The formula was finalized by comparing the in vitro dissolution profile.
Hence in present work, an attempt has been made to formulate Controlled
release matrix tablet of Isradipine by using hydrophilic matrix material.
Chapter-4 Plan of work
Dept of Pharmaceutics J. K. K. Nataraja College of Pharmacy36
4: PLAN OF WORK
The present work was carried out to formulate and evaluate the controlled
release matrix tablets of Isradipine using polymers like HPMC (E4M and E50).  The
study was proposed to carry out in the following stages.
Phase-I:
1. Pre-formulation study of pure drug.
2. Compatibility study.
 Fourier transform infrared spectroscopy (FT-IR)
3. Preparation of standard curve of Isradipine.
Phase-II:
1. Formulation of Isradipine controlled release matrix tablets.
2. Evaluation of matrix tablets.
 Physical evaluation.
 Drug content.
 Dissolution study.
3. Kinetic study.
Phase-III:
1. Accelerated stability study of the optimized formulation.
Chapter-5 Drug profile
Dept of Pharmaceutics J. K. K. Nattraja College of Pharmacy37
5. PROFILES
5.1. DRUG PROFILE
Isradipine:
Isradipine is a long-acting antihypertensive agent in vivo, exerting Primary
effects on vascular tissue with secondary negative chronotropic action. Potent and
selective L-type voltage-gated Ca2+ channel blocker. It belongs to dihydro pyridine
class.
Structure:
Table no: 3. Physico – Chemical Properties
Description Yellow crystalline solid
Chemical name 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-
pyridinecarboxylic acid methyl 1-methylethyl ester
Molecular formula C19H21N3O5
Molecular weight 371.39
Solubility Isradipine is practically insoluble in water (<10mg/L at
37°C), but is soluble in ethanol and freely soluble in acetone,
chloroform and methylene chloride.
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Site and Mode of Action:
Possibly by deforming the channel, inhibiting ion-control gating mechanisms,
and/or interfering with the release of calcium from the sarcoplasmic reticulum,
Isradipine inhibits the influx of extracellular calcium across both the myocardial and
vascular smooth muscle cell membranes. The resultant inhibition of the contractile
processes of the myocardial smooth muscle cells leads to dilation of the coronary and
systemic arteries and improved oxygen delivery to the myocardial tissue.
Pharmacokinetics:
Absorption and distribution;
Isradipine is 90%-95% absorbed and is subject to extensive first-pass
metabolism; resulting in a bioavailability of about 15%-24%.administration of
Isradipine with food significantly increases the time to peak by about an hour, but has
no effect on total bioavailability of the drug. Isradipine is 95% bound to plasma
protein.
Metabolism and excretion;
Isradipine undergoes extensive first-pass metabolism; Peak plasma
concentrations occur about2 hours after oral dosage Isradipine is extensively
metabolized in the liver, at least partly by the cytochrome P450isoenzyme CYP3A4.
About 70% of an oral dose is reported to be excreted as metabolites in urine, the
remainder in faeces. The terminal elimination half-life is often stated to be about 8
hours although a value of less than 4 hours has also been reported. In single-dose and
steady-state studies of the pharmacokinetics of Isradipine in 9 hypertensive subjects
using a specific high performance liquid chromatographic assay, Isradipine was found
to be rapidly absorbed with peak concentrations occurring 1.2(steady state) to 1.5
(single dose) hours after dosing.
Functional category In the treatment of Hypertension, vasodilation.
Pharmacopoeial
status
USP
Storage conditions Store in air tight containers, Protect from light.
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The mean terminal elimination half-life at steady state was 3.8 hours,
suggesting that duration of action is likely to be short and that Isradipine would need
to be given at least twice daily. There was considerable inter individual variation in
the pharmacokinetics. In an earlier study in healthy subjects the effective half-life of
Isradipine was calculated to be 8.8 hours, but radiolabelled Isradipine was used and
the assay method might have been less specific for unchanged drug.
Table no: 4. Pharmacokinetics-Pharmacodynamics
Parameters Data
Tmax 1.5 hr
Bioavailability 15-24%.
Cmax 1ng/ml/mg
Volume of distribution(VD ) 3L/Kg
Clearance (CLT ) 1.4L/min
Biological half life Biphasic with initial half of 1½-2hr,terminal half
life of 8hr.
Site and Mechanism of absorption Oral absorption
Serum protein binding Highly serum protein bound (95%)
Route of metabolism Rapidly metabolized in liver
Metabolites Six metabolites have been characterized in blood
and urine with the mono acids of pyridine
derivative and a cyclic lactone product
accounting for ˃75% of the material identified.
Activity of metabolites Have very little or no activity
Chapter-5 Drug profile
Dept of Pharmaceutics J. K. K. Nattraja College of Pharmacy40
Route of excretion Approximately 60-65% is excreted in urine and
25-30%in faeces.
Route of administration Oral
Indications Hypertension.
Adverse effects Symptoms of overdose include lethargy, sinus
tachycardia, and transient hypotension.
Drug Interactions with Isradipine:
Using this medicine with any of the following medicines is not recommended.
Bepridil, Cisapride, Levomethadyl, Mefloquine, Mesoridazine, Pimozide,
Thioridazine, Ziprasidone
Using this medicine with any of the following medicines is usually not
recommended, but may be required in some cases. If both medicines are prescribed
together, your doctor may change the dose or how often you use one or both of the
medicines.
Amiodarone, vasopressin, trimethoprim, satolol, risperidone,
sulfamethoxazole, fluoxetine, amitriptylline.
Using this medicine with any of the following medicines may cause an
increased risk of certain side effects.
Amprenavir, Dalfopristin, Indinavir, Itraconazole.
Dosage:
Hypertension: Adults: the usual initial dose is 2.5mg twice daily; Maximum
dose 10 mg twice daily and doses increase to 20 mg daily if necessary.
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5.2. EXCIPIENT PROFILE
Table no: 5. Hypromellose
Synonyms Benecel, HPMC, Methocel, Hydroxy propyl methyl
cellulose
Description White or creamy white fibrous or granular, odorless,
tasteless powder.
Functional categories Coating agent, film former, rate controlling polymer for
sustained release, stabilizing agent, suspending agent,
viscosity builder.
Solubility Soluble in cold water, forming a viscous colloidal solution,
practically insoluble in mixtures of ethanol and
dichloromethane, mixtures of alcohol and water.
pH 5.5-8.0 for a 1%w/w aqueous solution.
Bulk density 0.341 g/cm3
Tapped density 0.557 g/cm3
Melting point Browns at 190-200 oC
Chars at 225-230 oC
Moisture content Absorbs moisture from the atmosphere.
Stability and storage
conditions
Stable between pH 3-11, should be stored in a well-closed
container in a cool and dry place.
Incompatibility Incompatible with some oxidizing agents.
Applications High viscosity grades may be used to retard the release of
drugs from a matrix at levels of 10-80%w/w in tablets and
capsules. Low viscosity grades are used in aqueous film
coating.
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Table no: 6. Dibasic calcium phosphate dehydrate
Synonyms Calcii hydrogenophosphas dihydricus; calcium
hydrogen orthophosphate dihydrate; calcium
monohydrogen phosphate dihydrate; Di-Cafos;
dicalcium orthophosphate; DI-TAB; E341;
Emcompress; phosphoric acid calcium salt (1 : 1)
dihydrate;
Empirical formula CaHPO4_2H2O
Molecular weight 172.09
Description White, odorless, tasteless powder or crystalline solid.
It occurs as monoclinic crystals.
Functional categories Tablet and capsule diluent
Solubility Practically insoluble in ethanol, ether, and water;
Soluble in dilute acids.
Loss on drying 24.5–26.5%(as per US pharmacopeia)
Stability and storage
conditions
Dibasic calcium phosphate dihydrate is a non
hygroscopic, relatively stable material. However,
under certain conditions the dihydrate can lose water
of crystallization. This has implications for both,
storage of the bulk material and coating and packaging
of tablets containing dibasic calcium phosphate
dihydrate.
The bulk material should be stored in a well-closed
container in a cool, dry place.
Incompatibilities Dibasic calcium phosphate dihydrate should not be
used to formulate Tetracycline antibiotics. Dibasic
calcium phosphate dihydrate has been reported to be
incompatible with Indomethacin, Aspirin, Aspartame,
Ampicillin, Cephalexin, and Erythromycin.
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Applications It is widely used as an excipient and as a source of calcium and
phosphorus in nutritional supplements. Two main particle-size
grades of dibasic calcium phosphate dihydrate are used in the
pharmaceutical industry. The milled material is typically used
in wet-granulated, roller-compacted or slugged formulations.
The ‘unmilled’ or coarse-grade material is typically used in
direct-compression formulations.
It is also used in toothpaste and dentifrice formulations for its
abrasive properties.
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Table no: 7. Magnesium stearate
Synonyms Dibasic magnesium stearate; magnesium distearate;
magnesiistearas; magnesium octadecanoate; octadecanoic
acid, magnesium salt; stearic acid, magnesium salt;
Description Magnesium stearate is a very fine, light white,
precipitated milled, impalpable powder of low bulk
density, having a faint odor of stearic acid and a
characteristic taste.
Solubility Practically insoluble in ethanol, ethanol (95%), ether and
water; slightly soluble in warm benzene and warm ethanol
Stability and storage
conditions
Magnesium stearate is stable and should be stored in a
well-closed container in a cool, dry place.
Incompatibilities Incompatible with strong acids, alkalis, and iron salts.
Avoid mixing with strong oxidizing materials.
Magnesium stearate cannot be used in products containing
aspirin, some vitamins, and most alkaloidal salts
Applications Magnesium stearate is widely used in cosmetics, foods,
and
Pharmaceutical formulations. It is primarily used as a
lubricant in
capsule and tablet manufacture at concentrations between
0.25%
And 5.0% w/w. It is also used in barrier creams.
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Table no: 8. Colloidal Silicone Dioxide.
Synonyms Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica;
fumedsilica;
Description Colloidal silicon dioxide is a sub microscopic fumed silica
with a particle size of about 15 nm. It is a light, loose, bluish-
white-colored, odorless, tasteless, amorphous powder.
Functional categories Adsorbent; anticaking agent; emulsion stabilizer; glidant;
suspending agent; tablet disintegrant; thermal stabilizer;
viscosity-increasing agent.
Solubility Practically insoluble in organic solvents, water, and acids,
except hydrofluoric acid; soluble in hot solutions of alkali
hydroxide. Forms a colloidal dispersion with water. For
Aerosil, solubility in water is 150 mg/L at 258C (pH 7).
pH 3.5-5.5 for a 4%w/w  aqueous  solution
Bulk density 0.029–0.042 g/cm3
Melting point 1600 0C
Stability and storage
conditions
Colloidal silicon dioxide is hygroscopic but adsorbs large
quantities of water without liquefying at a pH greater than
7.5 the viscosity increasing properties of colloidal silicon
dioxide are reduced.
Incompatibility Incompatible with diethylstilbestrol preparations
Applications Colloidal silicon dioxide is also used to stabilize emulsions
and as a thixotropic thickening and suspending agent in gels
and semisolid preparations. (5Colloidal silicon dioxide is
also used as an adsorbent during the preparation of wax
microspheres; as a thickening agent for topical preparations;
and has been used to aid the freeze-drying of nano capsules
and nano sphere suspensions.
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Table no: 9. Polyethylene Glycol
Synonyms Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogol;
PEG; Pluriol E; polyoxy ethylene glycol.;
Description Polyethylene glycol grades 200–600 are liquids; grades 1000
and above are solids at ambient temperatures. Liquid grades
(PEG 200–600) occur as clear, colorless or slightly yellow-
colored, viscous liquids. They have a slight but characteristic
odor and a bitter, slightly burning taste. PEG 600 can occur as
a solid at ambient temperatures.
Functional categories Ointment base; plasticizer; solvent; suppository base; tablet
and capsule lubricant.
Solubility Liquid polyethylene glycols are soluble in acetone, alcohols,
benzene, glycerin, and glycols. Solid polyethylene glycols are
soluble in acetone, dichloromethane, ethanol (95%), and
methanol; they are slightly soluble in aliphatic hydrocarbons
and ether, but insoluble in fats, fixed oils, and mineral oil.
pH 4.5-5.5 for a 5%w/w.
Flash point 238 0C
Stability and storage
conditions
The temperature must be kept to the minimum necessary to
ensure fluidity; oxidation may occur if polyethylene glycols
are exposed for long periods to temperatures exceeding 508C.
However, storage under nitrogen reduces the possibility of
oxidation. Polyethylene glycols should be stored in well-
closed containers in a cool, dry place. Stainless steel,
aluminium, glass, or lined steel containers are preferred for
the storage of liquid grades.
Incompatibility All grades can exhibit some oxidizing activity owing to the
presence of peroxide impurities and secondary products
formed by autoxidation. Liquid and solid polyethylene glycol
grades may be incompatible with some colouring agents.
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Applications Polyethylene glycol has been used experimentally in
biodegradable polymeric matrices used in controlled-release
systems. (1) Useful as ointment bases. Can be used as
suppository bases, (3) for which they have many advantages
over fats.
Table no: 10. Isopropyl alcohol
Synonyms Di methyl carbinol,  isopropanol , 2-propanol.
Empirical formula C3 H8 O
Molecular wt 60.1
Description Clear , colorless, mobile, volatile, flammable liquid with
characteristic, spirituous odor & slightly bitter taste
Functional category Disinfectant,  solvent
Solubility Miscible with benzene, chloroform,   ethanol.
Soluble in acetone
Insoluble   in salt solutions.
Storage conditions Store in a airtight container in a cool & dry place
Incompatibility Incompatible with H2O2 & Nitric acid.
Salting out from  aqueous preparations by adding sodium
salts
Applications Tablets - Film forming agent & Granulating agent
70% v/v used as disinfectant
Not recommended for oral use
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6. MATERIALS AND METHODOLOGY
6.1. MATERIALS
Table no: 11. List of materials used in the formulation study
S.No. Name of  the ingredients Name of the Supplier
1
Isradipine GlaxoSmithKline Pharmaceuticals Ltd.,
Nashik
2.
Dicalcium phosphate
dehydrate (Calipharm D)
S.D. Fine chemicals Pvt. Ltd., Mumbai
5. Methocel E4M Strides Arco Labs, Bangalore
6. Methocel E50 Strides Arco Labs, Bangalore
7.
Poly ethylene glycol
(PEG -400)
S.D. Fine chemicals Pvt. Ltd., Mumbai
8. Isopropyl alcohol S.D. Fine chemicals Pvt. Ltd., Mumbai
9. Aerosil S.D. Fine chemicals Pvt. Ltd., Mumbai
10. Magnesium stearate S.D. Fine chemicals Pvt. Ltd., Mumbai
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Table no: 12. Lists of equipment and instruments used in the present study
s. no. equipment manufacturer model no
1 Electronic Balance Shimadzu AUX220
2 Sieves United Engineering Ltd. ASL00
3 Tap density Tester Electrolab ETD-020
4 Electromagnetic Sieve Shaker Electropharma EMS- 8
5 Laboratory Stirrer Remi RQT-124A
6 Rapid dryer Retsch TG-200
7 pH Meter Thermo Orion 2 Star
8 Dissolution test apparatus Electro lab USP XXII TDT-08L
9 Stability chambers Thermolab Standard
10 Hardness tester Pharmatest PTB-311E
11 Friabilator Electrolab EF-1W
12 Tablet Compression machine-
16Station
Cadmch Machinery co.
Pvt.Ltd
CM D3-16
13 Peristalic pump Electrolab PP-50V
14 IR moisture balance Sartorious SARTORIUS
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6.2. METHODOLOGY FOR DEVELOPMENT OF CONTROLLED
RELEASE MATRIX TABLET:-
6.2.1. PREFORMULATION STUDIES:
Preformulation testing was an investigation of physical and chemical
properties of a drug substance alone and when combined with excipients. It was the
first step in the rational and development of dosage forms.
Objective/purpose of preformulation study:-
Pre-formulation studies on active pharmaceutical ingredients (API), inactive
ingredients (Excipients), and their combinations were carried out to serve following
purposes:
i) To generate information useful in developing the formulation.
ii) To Finalize specifications of active pharmaceutical ingredients (API)
iii) To Study the compatibility between active and inactive ingredient
Scope:-
The use of preformulation parameters maximizes the chances in formulating an
acceptable, safe, efficacious and stable product.
Class: - Preformulation study can divide in to Two Subclasses.
I.API characterization,
II.Compatibility study
I. Active pharmaceutical ingredient (API) characterization:-
1. Organoleptic Evaluation: These are preliminary characteristics of any substance
which is useful in identification of specific material. Following physical properties of
Active Pharmaceutical Ingredients were studied. a) Color   b) Odor
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II. Determination of melting point:-
The melting point of isradipine was determined by capillary method, using
definite quantity of isradipine taken and replaced in apparatus and determined the
melting point and matched with the standards.
III. Loss on drying:-
1.0g of sample of isradipine was accurately weighed and the powder was kept
in a moisture balance apparatus for 3 min. At 105ºC and the moisture content was
calculated.
IV. SOLUBILITY STUDIES
Isradipine is classified under class II according to BCS i.e.; highly permeable
but low soluble. Solubility studies of Isradipine were conducted at all pH ranges from
1 to 7.4. The solubility of Active Pharmaceutical Ingredients was determined by
dissolving the highest unit dose of the drug in 250 mL of buffer adjusted between pH
1.0 and 7.4. For this purpose 0.1N HCl, pH 4.6 buffer, pH 6.8 buffer and 0.1%, 0.2%
Lauryl Dimethylamine Oxide in water, Purified water were used. Highest dose of the
drug i.e., 10mg was dissolved in 250 mL of medium and was kept untouched for 12
hours. Later on the insoluble drug was filtered off and diluted with sufficient amount
of the same solvent. The absorbance of the solution was determined 239 nm.
V. Powder Characterization
1. Angle of Repose: -
The angle of repose has been used to characterize the flow properties of solids.
Angle of repose is a characteristic related to inter particulate friction or resistance to
movement between particles. This is the maximum angle possible between surface of
pile of powder or granules and the horizontal plane.
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Tan  = h / r
 = Tan –1 h / r…………………………… Eq (3)
Where
 = angle of repose,
h = height,
r = radius.
A funnel was fixed at a height approximately of 2-4 cm over the platform. The
loose powder was slowly passed along the wall of funnel, till the cone of the powder
formed. The angle of repose was determined by measuring the height of the cone of
powder and radius of the heap of powder.
Table no.13: Flow Properties and Corresponding Angles of Repose
Flow Property Angle of Repose (degrees)
Excellent 25–30
Good 31–35
Fair - aid not needed 36–40
Passable - may hang up 41–45
Poor - must agitate, vibrate 46–55
Very poor 56–65
Very, very poor >66
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2. Bulk density:-
Bulk density was determined by pouring gently 20 gm of sample (Isradipine)
through a glass funnel into 50 ml graduated cylinder. The volumes occupied by the
samples were recorded. Bulk density was calculated as:
3. Tapped density:-
Tapped density was determined by using Electro lab density tester, which
consists of   a graduated cylinder mounted on a mechanical tapping device. An
accurately weighed sample of powder was carefully added to the cylinder with the aid
of a funnel. Typically, the initial volume was noted, and the sample is then tapped
(500, 750 or 1250 tapping) until no further reduction in volume is noted or the
percentage of difference is not more than 2%.
A sufficient number of taps should be employed to assure reproducibility for the
material in question. Volume was noted and taped density is calculated using
following formula.
4. Compressibility Index and Hausner ratio:-
In recent years the compressibility index and the closely related Hausner ratio
have become the simple, fast, and popular methods of predicting powder flow
characteristics. The compressibility index has been proposed as an indirect measure of
bulk density, size, shape, surface area, moisture content and cohesiveness of materials
because all of these can influence the observed compressibility index.
Both the compressibility index and the Hausner ratio were determined by using
bulk density and the tapped density of a powder.
Bulk density = weight of sample in gram /volume occupied by the
sample
Tapped density = Weight of sample in gram / Tapped volume
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Table no.14: Relation of flow property with Compressibility index and
Hausner’s ratio.
Compressibility
Index (%)
Flow
Character Hauser’s Ratio
10 Excellent 1.00–1.11
11–15 Good 1.12–1.18
16–20 Fair 1.19–1.25
21–25 Passable 1.26–1.34
26–31 Poor 1.35–1.45
32–37 Very poor 1.46–1.59
>38 Very, very poor >1.60
C.I = tapped-untapped×100/tapped.
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VI.DRUG EXCIPIENT COMPATIBILITY STUDIES
Drug Excipient Compatability Study by FTIR (Fourier Transform Infra-Red
Spectroscopy)
Drug and excipient were analysed by IR spectral studies by using KBr pellet
technique. IR spectrophotometry can be used to investigate and predict any physic-
chemical interactions between different components in a formulation and therefore it
can be applied to the selection of suitable chemical excipients.
The main aim of the study was to test whether there is any interaction between
the mixtures of polymers and active pharmaceutical ingredient (Isradipine).
In this method, the drug and KBr were mixed at the ratio of 1:100. Then these
mixtures were pressed in to a pellet. The FTIR spectra were recorded using KBr pellet
method. Spectra were recorded for pure drug, pure excipients and drug with
excipients.
VII. PREPARATION OF STANDARD CALIBRATION CURVE OF
ISRADIPINE
Preparation of media (0.2% of 30% Lauryl Dimethyl amine oxide):
Transferred 66.0 mL of 30 % Lauryl Dimethyl amine oxide in to a 10 Litre of
dearerated water and mixed well.
Method:
10mg of isradipine was accurately weighed and transferred into 100 ml
volumetric flask, it was dissolved and diluted to volume with 0.2% Lauryl dimethyl
amine oxide in water to give stock solution containing 1000µg/ml. the standard stock
solution was then serially diluted with 0.2% Lauryl dimethyl amine oxide in water to
give concentration of 1, 2, 3 upto 10µg/ml of isradipine. The absorbance was
measured at 239 nm using UV Spectrophotometer, the absorbance values were plotted
against concentration (µg/ml).
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6.2.2. FORMULATION OF ISRADIPINE CONTROLLED
RELEASE MATRIX TABLET
Based on preformulation data, wet granulation is used for developing matrix
type dosage form. The following formulations are prepared by maintaining the
effective processing conditions, NMT 50% RH and NMT 60 ºC temperature.
Formulation was done basically with strategies mentioned below
PROCEDURE FOR WET GRANULATION:
STEP 1. WEIGHING:
Weighed the required quantities of Isradipine, diluents (Dibasic Calcium Phosphate)
and other dry mix elements as per given in the table separately.
STEP 2.  SIFTING:
Co sifted the drug, diluent and HPMC E50 through #30 mesh and mixed the blend in
a poly bag for uniform distribution of Active Pharmaceutical Ingredients.
STEP 3.  LOADING AND GRANULATION:
Co sifted mixture is loaded into granulation apparatus and weighed required amount
of water for granulation.
STEP 4. DRYING:
Granules were dried at temperature at 35-59 °C until the Loss on Drying was
obtained.
STEP 5. SIZING OF GRANULES:
The granules obtained were sized through #30 mesh. Required quantity extra granular
material was weighed and passed through #30 mesh   along with granules.
STEP 6. LUBRICATION:
Required concentration of magnesium stearate was weighed, passed through #40
mesh   and blended with blend from step 5 for 1 minute.
STEP 7. COMPRESSION:
The granules obtained were compressed with 8mm standard concave punch using 16
station compression machines.
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Figure no.8: Formulation strategy of Isradipine 10 mg tablets.
STRATEGY
Blending Mix in
poly bag
Granulation
Time: 10 minutes
Inlet Temp-35-
39⁰C.Granulation Agent:PEG 400 followed
by IPA
Drying
Inlet Temp-35-
39⁰C. LOD-2-
3%
Sifting MESH: ≠ 30
MESH
Lubrication MESH: ≠ 40
MESH Time: 3
minutes
Magnesium Stearate
Compression 8.0mm, Round
shape, Standard concave punch
Avg.Wt:300±3.0
% Hardness: 7-
9Kp Thickness:
3.6-3.8
Isradipine, DCP,
E4M and E50
Sifting ≠30 MESH
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Table no.15: Tablets Compilation of Isradipine controlled release matrix tablet
S.
NO.
CONTENTS F1 F2 F3 F4 F5 F6 F7 F8 F9
(mg/tablet)
A. DRY MIX
1 Isradipine 10 10 10 10 10 10 10 10 10
2 Dibasic
calcium
phosphate
210 210 210 210 210 200 210 200 200
3 HPMC E4M 50 60 70 - - - 60 60 60
4 HPMC E50 - - - 50 60 70 15 20 30
B. BINDER
5 PEG-400 5 5 5 5 5 5 5 5 5
6 Isopropyl
alcohol
1 1 1 1 1 1 1 1 1
C. LUBRICATION
7 Aerosil 1 1.5 1.5 1.5 1 1 1.5 1 1
8 Magnesium.
Stearate
2 2 2 2 2 2 2 2 2
Average  weight 279 289 299 279 289 289 304 299 309
F=Formulation Batches
In F1: in the first trial F1,10 mg of isradipine,210 mg of DCP,50 mg of HPMC E4M
were co sifted and PEG 400 was used as binder and granulated , lubricated with
magnesium stearate  and compressed.
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In F2: same formula as that of F1, granulation is taken to that 60 mg of HPMC E4M
was added, lubricated and compressed.
In F3: same formula as that of F1, granulation is taken to that 70 mg of HPMC E4M
was added, lubricated and compressed.
In F4: same as that of F1, but here HPMC E4M was replaced for HPMC E50.
Isradipine, DCP and HPMC E50 were co sifted and PEG 400 was used as binder and
granulated, lubricated with magnesium stearate and compressed.
In F5: in formulation F5, in dry mix quantity of HPMC E50 first trial was increased
to 60mg and isradipine DCP, HPMC E50 were co sifted and PEG 400 was used as
binder and granulated , lubricated with magnesium stearate  and compressed.
In F6: in formulation F6, in dry mix HPMC E50 was increased to70mg, and DCP
decreased to 200 mg, then it was granulated, lubricated with magnesium stearate and
compressed.
In F7: in formulation F7, both polymers were used in different ratio, 60 mg of HPMC
E4M and 15 mg of HPMC E4M were added and co sifted PEG 400 was used as
binder and granulated, lubricated with magnesium stearate and compressed.
In F8: same as in F7, here quantity HPMC E50 was increased to 20 mg, granulated,
lubricated with magnesium stearate and compressed.
In F9: in formulation F9, HPMC E50 was increased to 30 mg and HPMC E4M was
60 mg was added, co sifted and PEG 400 was used as binder and granulated,
lubricated with magnesium stearate and compressed.
Chapter - 6 Materials And Methodology
Dept of Pharmaceutics J. K. K. Nattraja College of Pharmacy60
6.2.3. PHYSICHOCHEMICAL EVALUATION OF TABLET
Post compression parameters:
a) Shape of tablet:
The compressed tablets were examined under the magnifying lens for the shape
of tablet.
b) Tablet dimensions:
Diameters of the tablets were measured using a calibrated dial caliper. Three
tablets of each formulation were taken randomly and thickness was measured
individually.
c) Hardness test:
Hardness of the tablet was determined by using the Monsanto hardness tester.
The lower plunger was placed in contact with the tablet and a zero reading was taken.
The plunger was then forced against a spring by turning a threaded bolt until the tablet
fractured. As the spring was compressed a pointer rides along a gauge in the barrel to
indicate the force.
d) Thickness:
Thickness of the tablet was calculated by the use of vernier calipers. The
thickness of the tablet is measured in mm.
e) Friability test:
20 previously weighed tablets were placed in the apparatus. Which was given
100 revolutions and the tablets were reweighed. The percentage friability was
calculated by using the following formula,
Percentage friability = initial weight-final weight /initial weight × 100.
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f) Weight Variation:
20 tablets were selected and weighed collectively and individually. From the
collective weight, average weight was calculated. Each tablet weight was then
compared with average weight to ascertain whether it was within permissible limits or
not. Not more than two of the individual weights deviated from the average weight by
more than 7.5% for 300 mg tablets and none by more than double that percentage.
g) Drug content:
20 tablets of each formulation were weighed and powdered. The quantity of
powder equivalent to 100 mg of isradipine was transferred in to a 100 ml volumetric
flask and volume made up with 0.2% lauryl dimethylamine in water. The mixture was
then filtered to remove un-dissolved particle, further 1ml of the above solution was
diluted to 10 ml with 0.2% lauryl dimethylamine in water and absorbance of the
resulting solution was observed at 239 nm.
IN-VITRO DISSOLUTION STUDY:
Dissolution parameters:
Medium : 0.2% Lauryl Dimethylamine Oxide (LDAO) in water
Apparatus : USP- Type II (Paddle)
Rpm : 50
Temperature : 370±0.50C
Medium volume : 1000ml
Procedure:
1000 ml of 0.2% Lauryl Dimethylamine Oxide (LDAO) in water was placed in
vessel and the USP apparatus –II (Paddle Method) was assembled. The medium was
allowed to equilibrate to temp of 37°C + 0.5°C. Tablet  was placed in the vessel and
Chapter - 6 Materials And Methodology
Dept of Pharmaceutics J. K. K. Nattraja College of Pharmacy62
the vessel was covered the apparatus was operated for 24 hours and then the medium
0.2% Lauryl Dimethylamine Oxide (LDAO) in water was taken and process was
continued from 0 to 24 hrs at 50 rpm. At definite time intervals of 5 ml of the
receptors fluid was withdrawn, filtered and again 5ml receptor fluid was replaced.
Suitable dilutions were done with receptor fluid and analyzed by
spectrophotometrically at 239 nm using UV-spectrophotometer.
6.3. KINETICS OF DRUG RELEASE:
To analyze the mechanism of release and release rate kinetics of the dosage
form , the data drug obtained were fitted into Zero order, First order, Higuchi matrix
and korsmeyer-Peppa’s  and the correlation (r) values were calculated for linear
curves by regression analysis of the above plot. Based on the r-value, the best –fit
model was selected.
Zero order kinetics:
Drug dissolution from pharmaceutical dosage forms that do not disaggregate
and release the drug slowly, assuming that the area does not change and no
equilibrium conditions are obtained can be represented by the following equation,
Q t = Q o + K o t……………………………..Eq (4)
Where,
Q t = amount of drug dissolved in time t.
Q o = initial amount of the drug in the solution,
K o = zero order release rate constant.
Dosage forms following this profile, release same amount of drug per unit time, and it
is the ideal method of release for a controlled release product.
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First order kinetics:
To study the first order release rate kinetics, the release rate data were fitted to the
following
equation,
Log Qt= log Qo+ K1t/2.303………………………………..Eq (5)
Where,
Qt= the amount of drug released in time t,
Qo= the initial amount of drug in the solution
K1= the first order release constant.
In this way a graphic of the decimal log of the released amount of drug vs. time will
be linear.
The pharmaceutical dosage forms following this dissolution profile, such as
those containing water soluble drugs in the porous matrices would release the drug in
a way that is proportional to the amount of drug remaining in its interior.
Higuchi model:
Higuchi developed several theoretical models to study the release of water
soluble and low soluble drugs incorporated in semisolids and/or solid matrices.
Mathematical expressions were obtained for drug particles dispersed in a uniform
matrix behaving as the diffusion media. And the equation is,
Qt= KH ·t1/2…………………………………………………..Eq (6)
Where,
Qt= amount of drug released in time t,
KH = Higuchi dissolution constant.
It describes drug release as a function of square root of time that is dependent on
diffusion process based on Fick’s law.
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Krosmeyer and Peppas release model:
For prediction of mechanism of drug release through polymeric system
Korsmeyer and Peppas, in 1983 developed a mathematical equation, relating
exponentially the drug released to the elapsed time. It is a simple semi empirical
equation also called as Power law.
To study this model the release rate data are fitted to the following equation,
Mt / M∞ = K · t n………………………………………Eq (7)
Where,
Mt / M∞ = the absolute cumulative of drug release at time t and infinite
time.
K = the release constant,
T = the release time,
N = the diffusion coefficient for the drug release that is dependent on the
shape of the matrix dosage form.
Table No.16: Release Kinetics
DIFFUSION
EXPONENT
Release Exponent(n)
OVERALL SOLUTE DIFFUSION MECHANISM
Drug Transport Mechanism
0.45
0.5
Fickian Diffusion
SLAB/CYLINDER
0.45<n<0.89
0.5<n<1.0
Anomalous (Non Fickian)Transport
SLAB/CYLINDER
0.89
1.0
Case II
SLAB/CYLINDER
n>0.89
n>1.0
Super Case II Transport
SLAB/CYLINDER
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From the Table 16, it is clear that when the exponent n takes a value of 1.0, the
drug release rate is independent of time. This case corresponds to zero order release
kinetics. For slabs, the mechanism that creates the zero-order release is known to
polymer scientists as case-II transport. Here the relaxation process of the
macromolecules occurring upon water imbibitions into the system is the rate
controlling step. The value of n= 0.5 indicates drug release is Fickian in nature. Thus,
Equation has two distinct physical meanings in the two special cases of n=0.5
(indicating diffusion-controlled drug release) and n=1 (indicating swelling-controlled
drug release). Values of n between 0.5 and 1.0 can be regarded as an indicator for the
superposition of both phenomena (anomalous transport). It has to be kept in mind that
the two extreme values for the exponent n, 0.5 and 1.0, are only valid for slab
geometry. Power Law is more comprehensive in describing the drug release as
compared to Higuchi.
6.4. STABILITY STUDY
An ethical drug manufacturer is committed to provide to his consumers drug
products, which are efficacious and safe. This can be ensured only by instituting a
sound programmed to study the stability of a product during its various phases of
development and to arrive at the proper storage conditions and the expiry period
under those conditions. This is a requirement in most of the countries and is stipulated
by the regulatory agencies of those countries. These studies would very quickly
identify the need, if any, to stabilize the active substance or the formulation, and save
invaluable time and effort from being spend on an unmarketable formulation. With
the recent trend towards globalization of manufacturing operation, it is imperative that
the final product be sufficiently rugged for marketing worldwide under various
climatic conditions including tropical, subtropical and temperate.
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Storage conditions
In general, a drug product should be evaluated under storage condition that
tests its stability and if applicable, its sensitivity to moisture or potential for solvent
loss. The storage condition used for stability studies were accelerated condition
(400C±20C/75% ± 5% RH) as per ICH guidelines. Stability study was carried out for
for the optimized formulation. Tablet of optimized formulation were striped packed
and kept in stability chamber for 3 month on above mention temperature.
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7. RESULTS AND DISCUSSION
7.1. Preformulation Studies
I. Organoleptic evaluation
Yellow colored fine crystalline powder odorless.
II. Melting point determination
Melting point of Isradipine was given in table no.17; it indicates purity of the drug
sample
Table no.17: Melting point observation
Test Specification Observation
Melting point 168-1700C 1690C
III. Loss on drying
It was determined as per procedure given in methodology. The results are illustrated
in following table
Table no.18: Observation for Loss on drying
Test Specification Observation
Loss on drying Not more than 0.5% 0.27%
IV. Solubility study
The solubility studies of Isradipine in water / buffer solutions were carried out
to know the solubility and decide the appropriate dissolution medium. Table 6 shows
the solubility data of of Isradipine in water/ buffer solutions.
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Table no.19: Solubility study data of Isradipine
V. Powder characterization
The results are illustrated are the table given below. The given result is an
average of three determinations.
Table no.20: Determination of Powder characteristic
S.no Characteristics Results
1. Angle of repose 490.56’
2. Bulk density 0.39 g/ml
3. Tapped density 0.221 g/ml
4. Compressibility index 41.11%
5. Hausner’s ratio 1.698
Test Name of the buffer/solvent Observation
Solubility
Analysis
Water
0.1NHCl
PH 4.5 Acetate buffer
PH 6.8 Phosphate buffer
0.1%LDAO
0.2%LDAO
0.091mg/ml
0.037mg/ml
0.05mg/ml
0.06mg/ml
0.427mg/ml
0.654mg/ml
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VI. DRUG EXCIPIENTS COMPATIBILITY STUDY
FTIR-STUDY:
The FT-IR spectrum of pure Isradipine was compared with the FT-IR spectrum
of physical mixtures of isradipine (isradipine, HPMC E50, HPMC E4M).There was
mo appearance or disappearance of any characterstics peaks. This shows that there is
no chemical interaction between the drug and the polymers used in the tablets. The
presence of peaks at the expected range confirms that the materials taken for the study
are genuine.
Table no.21: FT-IR Peak of various components
Wave number in cm-1 Characteristic bands drug
900-670 C-H stretching 780 cm-1
1720-1700 C=O 1710 cm-1
1615-1510 CH-CH2CH2 1540 cm-1
2850-2815 O-CH3 2827 cm-1
1680-1620 C=C 1670 cm-1
1690-1590 C=N bending 1630 cm-1
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Figure no.9: FT-IR Spectrum of Isradipine
Figure no.10:  FT-IR Spectrum of ISRADIPINE+HPMC E4M
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Figure no.11: FT-IR Spectrum of isradipine +HPMC E50
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7.2. STANDARD CALIBRATION CURVE OF ISRADIPINE:
Standard curve of isradipine was determined by plotting absorbance(nm)
versus concentration (µg/ml) at 239 nm and it was found to follow the beer’s law in
the range of 1to10µg/ml. the results obtained are as follows:-
Table no.22: standard curve of isradipine
Sl no. Concentration(µg/ml) Absorbance
1 0 0
2 1 0.0906
3 2 0.1563
4 3 0.223
5 4 0.2901
6 5 0.3618
7 6 0.4199
8 7 0.4879
9 8 0.5801
10 9 0.6407
11 10 0.7184
Slope 0.071
Regression 0.998
The linear regression analysis was done on absorbance data points.
A straight line equation was generated to facilitate the calculation of amount of drug.
The equation is as follows.
(y=mx+c)
Where,
Y=absorbance, m=slope, x = concentration, c = intercept.
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Figure no.12: standard curve of isradipine
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7.3. EVALUATION OF ISRADIPINE CONTROLLED RELEASE
MATRIX TABLETS
a) Shape of tablet:
Visual examinations of tablets from F1 to F9 were found to be circular shape with no
cracks.
b) Tablet dimensions:
The dimensions determine for formulated tablets were found to be uniform in
formulation F1 to F9.
c) Hardness:
The hardness of all batches ranged from 5 to 10 kp which was sufficient to maintain
the mechanical strength.
d) Thickness:
The thickness of the formulations was found in the range of 3-5mm. The tablets
exhibited uniform thickness among the different formulations .It is depicted in table
no.
e) Weight variation test:
All the formulated tablets passed weight variation test as pr the pharmacopoeia limits
of ± 5%.
f) Friability:
The value of % friability of each batch was found to be in range of 0.37 to 0.91.
g) Drug content:
The percentage of drug content from F1 to F9 was found to be 98.91% to 99.94% of
Isradipine. The average drug content of 10 tablets of each formulation is depicted in
Table no. Good uniformity in drug content was found among different batches of the
tablets and the percentage content was within 10%.
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Table no.23:    Results of Physical Evaluation of tablet
Batch
code
Physical Parameters
Diameter
(mm)± S.D
Hardness
(Kg/Square
inch)
Thickness
(mm)
Weight
variation
Friability
(%)
Drug
content (mg)
±S.D
F1 13.09±0.040 6-7 3.8-4.2 1.44 0.72 99.22±0.08
F2 13.08±0.006 5-6 3.94 1.23 0.79 99.09±0.04
F3 13.09±0.067 6-.7 4.00 1.48 0.81 99.79±0.0
F4 13.08±0.070 7-8 2-2.5 1.63 0.86 99.83±0.05
F5 13.08±0.056 7-9 3.8-4.1 1.38 0.91 99.17±0.04
F6 13.08±0.056 7-9 4.8-5.0 1.24 0.75 99.52±0.08
F7 13.09±0.052 7-9 3-4 1.28 0.67 99.53±0.04
F8 13.10±0.040 7-9 3-4 1.20 0.61 99.35±0.02
F9 13.28±0.067 7-9 3.3-3.5 1.20 0.46 99.69±0.05
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7.3.1. DISSOLUTION STUDIES:
The dissolution was carried out for different experimental trials and also for
the innovator. The various results that are obtained are tabulated below. Dissolution
studies are carried out in the following media.
Medium :  0.2% LDAO in water
Type of apparatus : USP - II (paddle type)
RPM : 50 rpm
Volume : 1000 mL
Temperature : 37ºC± 0.50C
Time :  24 hours
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Dissolution profile for Isradipine controlled release matrix tablets:
Table no.24: Dissolution data for Isradipine formulation F1, F2 and F3
Time (hours) Cumulative percentage drug release
F1 F2 F3
0 0 0 0
2 12.0 12.16 13.0
4 20.25 22.65 24.30
6 32.61 35.14 36.42
8 45.36 49.31 52.34
10 61.72 64.45 67.71
12 71.88 75.67 77.67
16 80.36 81.65 88.62
24 90.73 91.12 92.87
Figure no.13: Dissolution profile for Isradipine formulation F1, F2 and F3
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Table no.25: Dissolution data for Isradipine formulation F4, F5 and F6
Time (hours) Cumulative percentage drug release
F4 F5 F6
0 0 0 0
2 24.29 24.7 22.17
4 37.43 36.42 33.72
6 52.13 52.0 51.14
8 65.82 64.79 61.32
10 76.55 75.41 72.63
12 88.38 82.62 84.27
16 98.68 97.0 93.05
24 _ _ _
Figure no.14: Dissolution profile for Isradipine formulation F4, F5 and F6
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Table no.26: Dissolution data for Isradipine formulation F7, F8 and F9
Time (hours) Cumulative percentage drug release
F7 F8 F9
0 0 0 0
2 13.01 15.01 17.00
4 23.0 25.26 30.16
6 36.30 39.84 43.80
8 55.0 57.06 60.04
10 68.40 69.29 74.39
12 82.01 84.17 89.00
16 89.08 91.10 94.11
24 94.15 96.30 99.08
Figure no.15: Dissolution profile for Isradipine formulation F7, F8 and F9
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Table no.27:  Comparative dissolution profile of F1 to F9
Figure no.16: Comparative Dissolution profile for Isradipine formulation F1 to
F9
Time
(hours)
Cumulative percentage drug release
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
2 13.0 12.16 12.0 24.29 24.7 22.17 13.01 15.01 17.00
4 24.30 22.65 20.25 37.43 36.42 33.72 23.0 25.26 30.16
6 36.42 35.14 32.61 52.13 52.0 51.14 36.30 39.84 43.80
8 52.34 49.31 45.36 65.82 64.79 61.32 55.0 57.06 60.04
10 67.71 64.45 61.72 76.55 75.41 72.63 68.40 69.29 74.39
12 77.67 75.67 71.88 88.38 82.62 84.27 82.01 84.17 89.00
16 88.62 81.65 80.36 98.68 97..0 93.05 89.08 91.10 94.11
24 92.87 91.12 90.73 _ _ _ 94.15 96.30 99.08
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7.3. KINETIC STUDIES:
Table no.28: Kinetics of Isradipine controlled release matrix tablet F9
S.no Time Log
time
Square
root of
time
% drug
release (q)
% drug
remaining
(100-q)
Log(q) Log
(100-q)
F9 F9 F9 F9
1 0 - 0 0 100 - 2
2 2 0.3 1.41 17.00 83 1.23 1.91
3 4 0.6 2 30.16 69.84 1.47 1.84
4 6 0.8 2.45 43.80 56.2 1.64 1.74
5 8 0.9 2.83 66.04 33.6 1.81 1.52
6 10 1 3.16 74.39 25.61 1.87 1.40
7 12 1.1 3.46 98.00 11 1.94 1.04
8 16 1.2 4 94.11 5.89 1.97 0.77
9 24 1.4 4.90 99.08 0.92 1.99 0.03
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ZERO ORDER KINETICS: S
Figure no.17: Zero order plot of F9
FIRST ORDER KINETICS:
Figure no.18: First order plot of F9
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HIGUCHI PLOT:
Figure no.19: Higuchi plot of F9
KORESMEYER PEPPAS PLOT
Figure no.20: Koresmeyer-peppas plot of F9
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KINETIC VALUES OBTAINED FROM PLOTS OF F9
FORMULATION OF ISRADIPINE
Table no.29: compilation of results from all the mathematical models applied to
the optimized formulation.
7.4. ACCELERATED STABILITY STUDIES
Isradipine controlled release matrix tablets were evaluated for accelerated
stability studies at 400C / 75 % RH condition. The stability details / results are
presented as below.
Storage Condition: 400C / 75 % RH
Pack: HDPE (High Density Polyethylene) Container
Storage Period: 1 month, 2 months and 3 month
Formulas Zero
order
R2
First
order
R2
Higuchi
R2
Korsmeyer-
peppas
R2
n
Mechanism
of drug
release
F9 0.974 0.826 0.972 0.6574 0.758 Zero order
non fickian
diffusion
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Cumulative Dissolution profile of tablets after 1st month, 2nd month and 3rd
month stability of F9:
Table no.30: comparative dissolution data
Time in
hours
Cumulative % drug release
1st month 2nd month 3rd month
0 0 0 0
2 17 16.99 16.93
4 30.1 30.07 30.02
6 43.73 43.69 43.61
8 65.89 65.82 65.79
10 74.27 74.21 74.19
12 88.95 89.9 88.87
16 94.08 94.08 94
24 99.02 99.02 98.99
Figure no.21: Dissolution Profile After 1st month, 2nd month and 3rd month
stability of F9
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7.5. DISCUSSIONS
7.5.1. Preformulation studies of pure drug
Morphological characteristics such as colour, odour, form etc; of isradipine
were studied. As the API is found to be yellow colour and odourless.
The Melting point of isradipine lies in the range between 168-170˚C, which
indicates the purity of the drug and also indicating that drug has less sensitivity for
drying temperatures.
The solubility of isradipine was analysed in various media at different pH. It
was found that the drug was insoluble in water and soluble in Acetone, Ethanol
Isopropyl alcohol and Dichloro methane. Based on solubility the dissolution media
was selected and it is also official media 0.2% Lauryl Dimethyl Amine Oxide in
water.
Flow properties of API were studied by performing tests like Angle of repose,
bulk density, tapped density, Carr’s index, Hausner’s ratio. The results indicate that
Angle of repose of pure drug is greater than 40 indicating poor flow properties. The
Carr’s index was found to be 27% indicating fair to passable. The Hausner’s ratio was
within the limits indicating free flowability. These results indicated the drug
possessed good flow properties and compressible characteristics.
7.5.2. Drug excipient compatibility studies:
IR spectra of physical mixture of drug and excipients, drug alone showed no
significant shift or reduction in intensity of peaks of isradipine. The studies showed
that there was no interaction or physical change between the drug and excipients. So
the selected excipients were found to be compatible with the drug.
7.5.3. Preparation of calibration curve
Estimation of isradipine was performed by UV spectrophotometric method. The
method obeyed Beer’s of drug and law in the concentration range of 0-10µg/ml. Thus
the method was found to be suitable for estimation of isradipine content in various
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products and in vitro dissolution studies. The result was showed that there was no
shown in Fig 12.
7.5.4. Formulation studies of isradipine Controlled release matrix tablets:
Isradipine along with other excipients was formulated into tablets by wet
granulation methods as per the formulae given in the table no.15. HPMC was used in
graded amounts as to control the rate of release. Isopropyl alcohol and PEG in
suitable ratios were used as granulating agents.
All the tablets prepared were found to contain the drug with in 99.46±4 %
given in table no. 23. Hardness of the tablets was in the range of 5-9 kg and was
satisfactory. The % weight loss in the friability test was less than 0.5 in all the tablets
prepared.
Thus all the tablets were found to be of good quality and fulfilling all the
official and other requirements of compressed tablets.
Among all the tablets formulated, formulation  F9 prepared by wet granulation
gave the highest dissolution(99.08%) in a controlled release manner.So formulation
F9 was considered as best and optimized for the preparation of tablets of isradipine
prepared by wet granulation.
The dissolution data and dissolution profiles of isradipine controlled release
matrix tablets formulated were given in table no. 27 and shown in figure no 16.
7.5.5. Release mechanism
Based on the “n” value of 0.758 obtained for F9 formulation, the drug release
was found to follow Anomalous (non-Fickian) diffusion. This value indicates a
coupling of the diffusion and erosion mechanism (Anomalous diffusion) and indicates
that the drug release was controlled by more than one process.
Also, the drug release mechanism was best explained by zero order equation as
the plots showed the highest linearity (r2 = 0.9743), followed by Higuchi’s equation
(r2 = 0.9729). As the drug release was best fitted in zero order kinetics, it indicated
that the rate of drug release is concentration independent.
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7.5.6. Accelerated stability study
Stability studies were carried out at 40°C and 75% RH for three month
(Climate Zone IV condition for accelerated stability testing) to access their long term
stability. The protocol of stability studies were in compliance with the guidelines in
the WHO document for stability testing for product  intended for the global market.
After storage the formulation was subjected to physical evaluation and % drug release
after storage condition of 40°C and 75%RH for three month shows not significant
change. The stability studies result is shown in table no.30 and figure no.21.
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8. SUMMARY AND CONCLUSION
8.1. Summary
The aim of this study was to develop the Isradipine Controlled Release Matrix
tablets. Isradipine is long acting hypertensive agent, which is used in the treatment of
hypertension. In this study Isradipine matrix tablets were prepared by using excipients
like HPMC E50 and HPMC E4M,  (were used as matrix formers) and formulated by
wet granulation method, were subjected to physicochemical and in vitro dissolution
studies .
The conclusion of the study is as follows:
 In the preformulation studies, it was found that Isradipine has low solubility with
independent of PH, i.e. it is soluble in 0.2% LDAO in water.
 The FT-IR spectroscopy study was carried out to know the compatibility of the
excipients with Isradipine Results was found no significance changes in
characteristic peaks of drug in the recorded IR spectrum. Which it confirmed the
drug and other excipients used in the formulation are compatible with each other.
 The analytical method used in the present study was found to be suitable for the
estimation of Isradipine in different Medias which is indicated by the high
regression values obtained in the standard plots.
 The controlled release matrix tablets were prepared by wet granulation method
using PEG-400 and Isopropyl alcohol as binder and dibasic calcium phosphate as
diluents. Tablets prepared were found to be within the official limits with respect
to hardness, weight variation, drug content, thickness etc.
 Among all the nine formulations the release profile of trial F9 was found to be
able to control the rate of release for 24 hours.
 The best linearity was found in Higuchi’s equation plot for formulation indicating
the release of drug from matrix as a square root of time dependent process based
on Fickian diffusion.
 The dissolution data was also plotted in accordance with Korsmeyer-peppas
model (where n is the release exponent). Applicability of data indicating Non
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Fickian diffusion (or) Anomalous Transport as mechanism of drug release. Non
Fickian diffusional release occurs by the usual molecular diffusion of the drug due
to a chemical potential gradient.
 The stability study for the selected formulation F9 was performed as per ICH
guidelines. Stability study is carried out for three months at 40°C; 75% RH,
according to ICH guidelines. The tablets were tested for release during the
stability period and confirmed that results were found within the limits.
 The stability data reveals that the F9 showed a negligible change in drug content
after storage in various conditions for three months according to ICH guidelines.
Chapter-8 Summary and Conclusion
Dept of Pharmaceutics J. K. K. Nattraja College of Pharmacy91
8.2. Conclusion
By observing the results it can be concluded that formulation-F9 containing
Isradipine 10 mg per tablet and developed employing dibasic calcium phosphate and
Hydroxy propyl methyl cellulose gives better controlled release profile compare with
other formulation.
No significant change was observed in the drug content, physical properties and
dissolution rate of these tablets after the storage period of three months at 40o C and
75% RH. Hence the study resulted in the development of Isradipine Controlled
Release Matrix tablets comparable to the innovator product for Isradipine fulfilling
the objective of the study.
The identified formula shall be utilized for the formulation development and
other studies for successful launching of the product as it was proved to be stable and
robust, cost effective compared to osmotic device.
Hence the above study demonstrated that combination of various significant
viscosities of hydrophilic polymers and wet granulation ratios could be successfully
employed for formulating controlled release matrix tablet of isradipine. This can be
expected to reduce the frequency of administration and decrease the dose dependent
side effects associated with repeated administration of conventional isradipine tablets.
Hence it can be concluded that once daily controlled release tablet of isradipine
having satisfactory controlled release profile which may provide an increased
therapeutic efficacy thereby improving bioavailability and patient compliance. The
developed formulation overcomes and alleviates the drawback and limitation of
controlled Isradipine Controlled release preparations thereby fulfilling the objective of
the study.
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